Conferences: ECNP


ECNP 2023

Onset, Duration, and Severity of Adverse Events With KarXT (Xanomeline–Trospium) in the Randomised, Double-Blind,  Placebo-Controlled Phase 3 EMERGENT-3 Trial

ECNP 2023

Categorical Response Rates, Time Course of Response,and Symptom Domains of Response With KarXT(Xanomeline–Trospium) in the EMERGENT-3 Trial

ECNP 2022

Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial (EMERGENT-2)

ECNP 2021

KarXT Treatment Improves Cognitive Performance in Cognitively Impaired Patients with Schizophrenia: A Post hoc Analysis of the Phase 2 EMERGENT-1 Study

ECNP 2020

Phase 2 Trial Results of KarXT (Xanomeline + Trospium) in Patients With Schizophrenia: Superior Efficacy to Placebo Across Positive and Negative Symptoms and a Favorable Safety/Tolerability Profile